Market success of Novo Nordisk’s obesity drug likely to be delayed in Japan, says GlobalData

In March 2023, Japan’s Ministry of Health and Labor Welfare approved Novo Nordisk’s once-weekly subcutaneous glucagon-like peptide-1

Novo Nordisk and Flagship Pioneering partner to create a portfolio of transformational medicines

Pioneering Medicines and Novo Nordisk Bio Innovation Hub will leverage Flagship Pioneering’s bioplatform companies to create a portfolio of research programmes within cardiometabolic and rare diseases

NORD announces over US $ 100,000 in grant funding available for rare disease research

Three RFPs now open for qualified researchers through NORD's Jayne Holtzer rare disease research grants program

Porton Advanced and Sinorda Biomedicine collaborate for cell therapy development for solid tumours

Under the agreement, Porton Advanced will provide services to accelerate the development, production and registration of breakthrough cell therapies currently being developed by Sinorda Biomedicine

Novo Nordisk expands research collaboration for biologic medicines

This collaboration has resulted in several high-impact scientific publications describing breakthrough inventions, including the SOMA robotic pill, which has subsequently been licensed exclusively to Novo Nordisk for clinical development

Novo Nordisk India launches world’s first and only GLP-1 RA, oral semaglutide

Oral semaglutide is a co-formulation of GLP-1RA semaglutide with an absorption enhancer SNAC which protects semaglutide from undergoing degradation in the stomach

Nova Nordisk to invest 17 bn Danish kroner to expand capacity in Denmark

The investment will establish additional capacity across the entire global value chain from manufacturing of active pharmaceutical ingredients (API) to assembly and packaging, with the vast majority being invested in API capacity

Novo Nordisk to acquire Dicerna Pharmaceuticals for US $ 3.3 bn

Dicerna develops RNAi-based therapies to selectively silence genes that cause or contribute to disease

EMA backs higher-dose Wegovy, clearing path for greater weight loss option in Europe

Trump clinches historic deal as Lilly, Novo slash U.S. weight-loss drug prices

Agreements mark a major victory in the President’s long-term pledge to lower prescription drug costs for Americans